AN2 Therapeutics, Inc. (ANTX)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch ANTX
See up to 3 months of ANTX. The 7-day demo opens the 1M and 3M ranges and puts ANTX on your watchlist.
Start 7-day demoLatest ANTX insider trades
About AN2 Therapeutics, Inc. (ANTX)
AN2 Therapeutics, Inc. is an SEC registrant, filing under CIK 0001880438, classified as pharmaceutical preparations. It is grouped with Health Care companies on this site.
ANTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 2,098 | $12K |
| Open-market sale | 9 | 52,901 | $318K |
| Grant or award | 5 | 355,137 | |
ANTX insider transactions (Form 4)
3872 Form 4 filings on record, the earliest from Nov 5, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sarah Joanne Williams - Officer | Open-market sale | Common Stock | 327 footnote F1 | $1.06 | $347 | |
| ||||||
| Joshua M. Eizen - Officer | Grant or award | Common Stock | 50,000 footnote F1 | $0.00 | - | |
| Joshua M. Eizen - Officer | Grant or award | Stock Option (right to buy) | 100,000 | $0.00 | - | |
| ||||||
| Lucy Day - Officer | Grant or award | Common Stock | 38,000 footnote F1 | $0.00 | - | |
| Lucy Day - Officer | Grant or award | Stock Option (right to buy) | 77,000 | $0.00 | - | |
| ||||||
| Sarah Joanne Williams - Officer | Grant or award | Common Stock | 48,375 footnote F1 | $0.00 | - | |
| ||||||
| Eric Easom - Officer | Grant or award | Common Stock | 112,250 footnote F1 | $0.00 | - | |
| Eric Easom - Officer | Grant or award | Stock Option (right to buy) | 224,500 | $0.00 | - | |
| ||||||
| Sanjay Chanda - Officer | Grant or award | Common Stock | 38,000 footnote F1 | $0.00 | - | |
| Sanjay Chanda - Officer | Grant or award | Stock Option (right to buy) | 77,000 | $0.00 | - | |
| ||||||
| Gilbert Lynn Marks | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Robin Shane Readnour | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Stephanie Wong | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Patricia A. Martin | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Melvin K. Spigelman | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Kabeer Aziz | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
 Margaret M. Fitzpatrick | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Joseph S. Zakrzewski | Grant or award | Stock Option (Right to Buy) | 20,400 | $0.00 | - | |
| Kabeer Aziz | Grant or award | Common Stock | 11,560 footnote F1 | $0.00 | - | |
| ||||||
| Patricia A. Martin | Grant or award | Common Stock | 3,650 footnote F1 | $0.00 | - | |
| ||||||
| Gilbert Lynn Marks | Grant or award | Common Stock | 11,560 footnote F1 | $0.00 | - | |
| ||||||
| Lucy Day - Officer | Open-market sale | Common Stock | 3,295 | $1.00 | $3K | |
| Lucy Day - Officer | Open-market sale | Common Stock | 5,512 | $1.01 | $6K | |
| Stephen David Prior - Officer | Open-market sale | Common Stock | 3,604 | $1.00 | $4K | |
| Stephen David Prior - Officer | Open-market sale | Common Stock | 2,858 | $1.01 | $3K | |
| Sanjay Chanda - Officer | Open-market sale | Common Stock | 3,295 | $1.00 | $3K | |
| Sanjay Chanda - Officer | Open-market sale | Common Stock | 5,956 | $1.01 | $6K | |
| Joshua M. Eizen - Officer | Open-market sale | Common Stock | 17,923 | $1.00 | $18K | |
| Joshua M. Eizen - Officer | Open-market sale | Common Stock | 6,931 | $1.01 | $7K | |
| Joshua M. Eizen - Officer | Open-market sale | Common Stock | 2,819 footnote F1 | $1.14 | $3K | |
| ||||||
| Stephen David Prior - Officer | Open-market sale | Common Stock | 765 footnote F1 | $1.14 | $872 | |
| ||||||
| Gilbert Lynn Marks | Grant or award | Common Stock | 10,367 footnote F1 | $0.00 | - | |
| ||||||
| Kabeer Aziz | Grant or award | Common Stock | 10,367 footnote F1 | $0.00 | - | |
| ||||||
| Patricia A. Martin | Grant or award | Common Stock | 3,274 footnote F1 | $0.00 | - | |
| ||||||
| Kabeer Aziz | Grant or award | Common Stock | 11,875 | $0.00 | - | |
| Gilbert Lynn Marks | Grant or award | Common Stock | 11,875 | $0.00 | - | |
| Patricia A. Martin | Grant or award | Common Stock | 3,750 | $0.00 | - | |
| Patricia A. Martin | Grant or award | Common Stock | 3,166 | $0.00 | - | |
Item 2.02, 9.01
Item 5.07
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Recent ANTX Form 144 notices of proposed sale
1An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Readnour Robin Shane | Director | 1,012,000 | $6.08M | View on EDGAR |
ANTX insider trading FAQ
What is the latest insider trade for ANTX?
AN2 Therapeutics, Inc. (ANTX) had 10 insider filings in the last 90 days, with the most recent on 2026-10-13. The full record for ANTX runs to 72 Form 4 filings, the earliest from 2024-11-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ANTX stock?
1 insider purchase of ANTX was filed in the last 90 days, totaling $12K.
How many insiders are selling ANTX stock?
9 insider sales of ANTX were filed in the last 90 days, totaling $318K.
Where can I see ANTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ANTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Gilbert Lynn Marks view on EDGAR
- - Patricia A. Martin view on EDGAR
- - Kabeer Aziz view on EDGAR
- - Cameron C. Trenor III view on EDGAR
- - Robin Shane Readnour view on EDGAR
- - Robin Shane Readnour view on EDGAR
- - Sarah Joanne Williams view on EDGAR
- - Margaret M. Fitzpatrick view on EDGAR
- - Robin Shane Readnour view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where ANTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ANTX with a 7-day demo
- ANTX on your watchlist
- Every ANTX Form 4 filing on record
- Up to 3 months of ANTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
